source
- Capricor Therapeutics receives second FDA rejection for Duchenne cell therapy deramiocelThe U.S. Food and Drug Administration issued a second complete response letter rejecting Capricor Therapeutics' cell therapy deramiocel for Duchenne muscular dystrophy. The agency said the data did…
- Sanofi weighs $40 billion Insmed acquisition, seen as strategic fit in respiratory marketAnalysts are reporting that Sanofi is considering buying Insmed, a biotech focused on respiratory therapies. The potential transaction could be valued at up to $40 billion, making it one of the lar…